Technical Analysis for GNLX - Genelux Corporation
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Crossed Above 20 DMA | Bullish | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Fell Below 20 DMA | Bearish | 3.84% | |
| New Downtrend | Bearish | 3.84% | |
| Wide Bands | Range Expansion | 3.84% | |
| New Uptrend | Bullish | -1.30% | |
| Wide Bands | Range Expansion | -1.30% | |
| Gapped Up | Strength | -1.30% | |
| Up 3 Days in a Row | Strength | -1.30% | |
| Up 4 Days in a Row | Strength | -1.30% |
| Alert | Time |
|---|---|
| Rose Above Previous Day's High | about 16 hours ago |
| Up 5% | about 16 hours ago |
| 60 Minute Opening Range Breakout | about 17 hours ago |
| Up 3% | about 17 hours ago |
| Up 2% | about 18 hours ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 02/28/2024
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small-cell lung cancer. The company is also developing V2ACT Immunotherapy for the treatment of pancreatic cancer; and V-VET1 to treat hematologic and solid cancer. The company was incorporated in 2001 and is headquartered in Westlake Village, California.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Cancer Clinical Medicine Immunotherapy Virotherapy Immunotherapies Non Small Cell Lung Cancer Ovarian Cancer Pancreatic Cancer Oncolytic Virus Experimental Cancer Treatments Transgene Sa Treatment Of Ovarian Cancer Treatment Of Pancreatic Cancer
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Cancer Clinical Medicine Immunotherapy Virotherapy Immunotherapies Non Small Cell Lung Cancer Ovarian Cancer Pancreatic Cancer Oncolytic Virus Experimental Cancer Treatments Transgene Sa Treatment Of Ovarian Cancer Treatment Of Pancreatic Cancer
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 40.98 |
| 52 Week Low | 3.06 |
| Average Volume | 119,508 |
| 200-Day Moving Average | 14.06 |
| 50-Day Moving Average | 5.06 |
| 20-Day Moving Average | 3.62 |
| 10-Day Moving Average | 3.49 |
| Average True Range | 0.41 |
| RSI (14) | 43.82 |
| ADX | 31.99 |
| +DI | 21.18 |
| -DI | 22.98 |
| Chandelier Exit (Long, 3 ATRs) | 3.66 |
| Chandelier Exit (Short, 3 ATRs) | 4.29 |
| Upper Bollinger Bands | 4.26 |
| Lower Bollinger Band | 2.99 |
| Percent B (%b) | 0.63 |
| BandWidth | 35.13 |
| MACD Line | -0.43 |
| MACD Signal Line | -0.59 |
| MACD Histogram | 0.1579 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 4.27 | ||||
| Resistance 3 (R3) | 4.28 | 4.12 | 4.19 | ||
| Resistance 2 (R2) | 4.12 | 4.00 | 4.12 | 4.16 | |
| Resistance 1 (R1) | 3.96 | 3.93 | 4.04 | 3.95 | 4.14 |
| Pivot Point | 3.80 | 3.80 | 3.85 | 3.80 | 3.80 |
| Support 1 (S1) | 3.64 | 3.68 | 3.72 | 3.63 | 3.44 |
| Support 2 (S2) | 3.48 | 3.61 | 3.48 | 3.42 | |
| Support 3 (S3) | 3.32 | 3.48 | 3.39 | ||
| Support 4 (S4) | 3.31 |
